Source: European Journal of Pharmaceutical Sciences. Unidade: FFCLRP
Subjects: ANTIFÚNGICOS, LEISHMANIOSE CUTÂNEA, FARMACOTERAPIA, FARMACOCINÉTICA
ABNT
TADINI, Maraine Catarina et al. Pharmacokinetic study of AmB-NP-GR: a new granule form with amphotericin B to treat leishmaniasis and fungal infections. European Journal of Pharmaceutical Sciences, v. 173, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2022.106173. Acesso em: 27 set. 2024.APA
Tadini, M. C., Fernandes, F. S., Ozelin, S. D., Melo, M. R. S. de, Mansur, A. L., Toledo, T. B. de, et al. (2022). Pharmacokinetic study of AmB-NP-GR: a new granule form with amphotericin B to treat leishmaniasis and fungal infections. European Journal of Pharmaceutical Sciences, 173, 1-9. doi:10.1016/j.ejps.2022.106173NLM
Tadini MC, Fernandes FS, Ozelin SD, Melo MRS de, Mansur AL, Toledo TB de, Albuquerque NCP de, Tavares DC, Marquele Oliveira F, Oliveira ARM de. Pharmacokinetic study of AmB-NP-GR: a new granule form with amphotericin B to treat leishmaniasis and fungal infections [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 173 1-9.[citado 2024 set. 27 ] Available from: https://doi.org/10.1016/j.ejps.2022.106173Vancouver
Tadini MC, Fernandes FS, Ozelin SD, Melo MRS de, Mansur AL, Toledo TB de, Albuquerque NCP de, Tavares DC, Marquele Oliveira F, Oliveira ARM de. Pharmacokinetic study of AmB-NP-GR: a new granule form with amphotericin B to treat leishmaniasis and fungal infections [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 173 1-9.[citado 2024 set. 27 ] Available from: https://doi.org/10.1016/j.ejps.2022.106173